Purpose: Antimuscarinic therapy for men with OAB and BOO is perceived as a potential risk
for urinary retention. Using pressure flow urodynamics, we evaluated the safety of …

In a study of patients with BOO and an overactive bladder, authors from Seoul and
Pittsburgh compared the use of doxazosin with or without tolterodine. The combination of the …

Purpose: We evaluated the efficacy, patient acceptability and side effect profile of
tolterodine, a new antimuscarinic agent for treating bladder overactivity. Materials and …

Previously available antimuscarinic therapies for overactive bladder are poorly tolerated due
to a high incidence of adverse events, notably dry mouth. Tolterodine is a bladder-selective …

OBJECTIVES: To examine the safety, efficacy, and tolerability of tolterodine in four
randomized, double-blind, parallel, multicenter, 12-week studies of patients with overactive …

Objective To compare the efficacy and tolerability of tolterodine with that of oxybutynin in
patients with an overactive bladder. Patients and methods A randomized, double‐blind …

Objectives. To summarize the efficacy and safety of tolterodine from the pooled data of four
multicenter, randomized, double-blind, placebo-controlled, dose-ranging, parallel-group …

Purpose: We compared the tolerability and clinical efficacy of tolterodine with those of
oxybutynin in patients with an overactive bladder using an upward oxybutynin dose titration …

Purpose: We compared the importance of patient age and gender relative to the intensity of
baseline symptoms of overactive bladder in the therapeutic response to the muscarinic …

This study compared the clinical efficacy (determined from micturition diaries) and safety of
12 weeks' treatment with either tolterodine 2 mg twice daily, oxybutynin 5 mg three times …